Skip to main content
Clinical Trials/IRCT201501183236N6
IRCT201501183236N6
Completed
Phase 2

Effect of L-arginine supplementation on biochemical and anthropometirc indices associated with cardiovascular diseases

Shiraz University of Medical Sciences0 sites75 target enrollmentStarted: TBDLast updated:

Overview

Phase
Phase 2
Status
Completed
Enrollment
75

Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
no limit to no limit (—)
Sex
All

Inclusion Criteria

  • both sexes; BMI higher than than 29\.9 kg/m2 or visceral obesity (BMI whithin25\- 29\.9 kg/m2 and wc more than 102 cm in men or more than 88 in women); acute or chronic inflammation; stable body weight 3 months before the start of the study (based on self report) absence of any current diet or supplement treatment; absence of antidiabetic, antihypertensive, antihyperlipidemic treatment; no history of ischemic heart disease; and normal renal and liver function. Exclusion criteria: Unwillingness to continue; the use of tobacco or alcohol during the study; taking any supplements other than the selected intervention; any disease or physiological changes that requires special treatment; failure to follow the intervention designing (not consuming dedicated supplement to the total amount less than 90% predicted or more than 3 days).

Exclusion Criteria

  • Not provided

Investigators

Similar Trials